Blood Reviews RSS feed: Articles in Press. This respected international journal, Blood Reviews , is a vital information resource, bringing together appraisals of clinical practice, and research from recognized experts. Specially commissioned articles from leading researchers and practitioners guarantee truly global coverage of all the sub-specialties of hematology. Blood Reviews publishes review articles covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the editors welcome suggestions from potential authors. They should first write a brief outline of an intended review and send this to Dr Trevor Baglin or to Dr Jacob M Rowe. http://www.bloodreviews.com//inpress?rss=yesElsevier Inc.en © 2012 Elsevier Ltd. All rights reserved. Blood Reviews0268-960X2012-05-04 © 2012 Elsevier Ltd. All rights reserved. healthpermissions@elsevier.comhttp://www.bloodreviews.com/article/PIIS0268960X12000331/abstract?rss=yesAbstract: There has been immense progress in the management of venous thromboembolism in recent years with increased awareness and adequate thromboprophylaxis proving successful in reducing the morbidity and mortality associated with this condition. One of the commonest complications of an initial venous thrombosis is the development of recurrent thrombosis. Unlike in the case of the first clot, the diagnosis and management of the recurrent episode remain a difficult issue. Even more challenging is the clinical situation where a new thrombus develops while the patient is being treated with anticoagulant medication for a previous clot. The clinical approach and management of these patients are complex, and require understanding of the differences in thrombus development in the different clinical circumstances.Recurrent venous thromboembolism while on anticoagulant therapy - Corrected ProofJecko Thachil10.1016/j.blre.2012.04.002Blood Reviews (2012)2012-05-04Blood Reviews2012-05-04REVIEWhttp://www.bloodreviews.com/article/PIIS0268960X1200032X/abstract?rss=yesAbstract: ABVD continues to be the standard of care for patients with advanced stage Hodgkin Lymphoma (HL) although escalated BEACOPP has improved survival in one randomized controlled trial (RCT). More intensive regimens have higher rates of acute and late toxicities and this poses significant issues for patients. Consolidation strategies such as radiation or autologous stem cell transplantation (ASCT) have not demonstrated an improvement in overall survival in RCTs.Novel technology and therapeutics are leading us to investigate new questions. Interim FDG-PET scanning is now being tested in prospective studies. Small, typically retrospective trials suggest that interim PET scans are independent markers of outcome and current trials are piloting the use of PET-adapted therapy. Targeted therapeutics have been evaluated in the relapsed and refractory setting and now show promising single agent activity. Agents including brentuximab vedotin (a conjugated anti-CD30 monoclonal antibody) and the histone deacetylase inhibitor panabinostat have reported encouraging single agent activity and a large study of brentuximab vedotin maintenance post ASCT is underway. Combination and maintenance trials are planned or ongoing in the primary treatment setting that will hopefully improve on the treatment standards of the past decade.This review will discuss the current standard of care in advanced stage HL, summarize some of the current data regarding interim FDG-PET scans and will conclude with some issues related to the development of new agents that are likely to be involved in the future standard of therapy.Treatment of newly diagnosed advanced stage Hodgkin lymphoma - Corrected ProofJieun Uhm, John Kuruvilla10.1016/j.blre.2012.04.001Blood Reviews (2012)2012-04-30Blood Reviews2012-04-30REVIEWhttp://www.bloodreviews.com/article/PIIS0268960X1200029X/abstract?rss=yesAbstract: Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis. The interval between first symptoms and actual diagnosis along the intrinsic heterogeneity of tissue tropism create a wide spectrum of presentations, both in terms of scope and depth of symptoms and signs and functional status of patients. In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction.What do I need to know about immunoglobulin light chain (AL) amyloidosis? - Corrected ProofAngela Dispenzieri, Morie A. Gertz, Francis Buadi10.1016/j.blre.2012.03.001Blood Reviews (2012)2012-04-27Blood Reviews2012-04-27REVIEWhttp://www.bloodreviews.com/article/PIIS0268960X12000306/abstract?rss=yesAbstract: Vitamin K-antagonists (VKA) are the most widely used anti-thrombotic drugs with substantial efficacy in reducing risk of arterial and venous thrombosis. Several lines of evidence indicate, however, that VKA inhibit not only post-translational activation of vitamin K-dependent coagulation factors but also synthesis of functional extra-hepatic vitamin K-dependent proteins thereby eliciting undesired side-effects.Vascular calcification is one of the recently revealed side-effects of VKA. Vascular calcification is an actively regulated process involving vascular cells and a number of vitamin K-dependent proteins. Mechanistic understanding of vascular calcification is essential to improve VKA-based treatments of both thrombotic disorders and atherosclerosis. This review addresses vitamin K-cycle and vitamin K-dependent processes of vascular calcification that are affected by VKA. We conclude that there is a growing need for better understanding of the effects of anticoagulants on vascular calcification and atherosclerosis.Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists - Corrected ProofMartijn L.L. Chatrou, Kristien Winckers, Tilman M. Hackeng, Chris P. Reutelingsperger, Leon J. Schurgers10.1016/j.blre.2012.03.002Blood Reviews (2012)2012-04-20Blood Reviews2012-04-20REVIEW